Launch Effectiveness Assessment
What will accelerate—or block—adoption in the first 12 months?
Combine HCP and payer research with competitor tracking to identify adoption barriers, priority segments and launch actions.
Pharma market research that shows what will move uptake.
Know which physicians, payers and patients will decide your launch, and what each needs to see, before you commit budget.
Why expert-led primary research
In life sciences, access alone is not enough.
The value comes from reaching the right stakeholder, asking a scientifically informed question and connecting what you hear across the market.
Science-ledQuestions framed with therapy-area and clinical context
Right accessKOLs, HCPs, payers, providers, labs and executives
ConnectedInterviews, surveys, fieldwork and market data in one view
RepeatableOne-off answers, dashboards and longitudinal trackers
Point solutions
Pharma & Biotech research solutions.
Not research organized by method. Each point solution starts with the decision on your desk and the stakeholders who shape it, combining expert interviews, primary research and market evidence into a defined answer.
Launch & commercial performance
Brand & Launch Pulse Tracker
Where is brand momentum building, stalling or being lost—and why?
Track HCP, payer and account signals on awareness, preference, prescribing, access and competitor activity to guide decisions.
HCP Opportunity Segmentation
Which HCPs, institutions and accounts offer the greatest opportunity?
Segment stakeholders by patient potential, influence, behavior and access to sharpen targeting and territory priorities.
Access, value & experience
Pricing & Access Benchmark
How do price, reimbursement and evidence expectations differ by market?
Benchmark payer criteria, access pathways and price corridors to reveal the conditions required for sustainable access.
Payer & Value Message Testing
What will determine coverage—and which value messages will support it?
Interview payer and HTA decision-makers to test messages and surface evidence thresholds, trade-offs and access barriers.
Patient Journey & Care Pathway
Where do patients fall out of the diagnosis, treatment or support journey?
Map patient and caregiver experience with HCP perspectives to identify friction, unmet need and adoption barriers.
Medical & clinical intelligence
Pipeline & Asset Intelligence
How is the treatment landscape changing—and where will our asset fit?
Combine pipeline tracking with KOL interpretation to assess differentiation, treatment shifts and competitive pressure.
Practice & Care Delivery Intelligence
How is care delivered in practice—and what shapes treatment choice?
Map treatment pathways, clinical workflows and care-delivery constraints through HCP and multidisciplinary stakeholder research.
KOL & Scientific Insight
How are experts interpreting the science, unmet need and emerging data?
Moderate KOL and physician research to identify scientific questions, evidence gaps and communication priorities.
Portfolio & competitive moves
Therapy Area Opportunity
Which indications, segments and unmet needs deserve investment?
Combine expert, payer and market evidence to rank growth spaces by need, feasibility and competitive intensity.
Partner & Asset Screening
Which assets, technologies or partners merit deeper diligence?
Test clinical promise, customer relevance and execution risk through expert validation of shortlisted opportunities.
Competitor & Entrant Tracking
What are competitors likely to do next, and what changes for us?
Track trials, evidence, messaging and launches, translating signals into implications for positioning and priorities.
Coverage
Across the asset lifecycle. Across the decision ecosystem.
Our work follows an asset from opportunity assessment through development, access, launch and in-market growth—connecting the stakeholder groups that shape each decision.
01Discovery & Asset Strategy
02Clinical Development
03Medical Affairs
04Market Access
05Launch & Commercial
06In-Market Growth & Portfolio
Stakeholders
KOLs & Academic ExpertsTreating Physicians & HCPsInvestigators & Site TeamsPayers, HTA & FormularyHospitals, Labs & ProcurementPatients & AdvocacyIndustry Leaders & Partners
Therapy areas
OncologyImmunologyRare DiseaseCardiovascularCNSRespiratoryDiagnostics & Devices
Organizations
PharmaBiotechMedTechDiagnostics & IVDHealthcare TechnologyHealthcare Services
Three illustrative examples
Three examples built around the decision.
The mix changes with the question. What remains constant is a defined evidence plan and a decision-ready answer.
01
Test launch adoption
The question
What will drive or block adoption of a new therapy in its first year?
Evidence mix
KOL and physician research, payer interviews, pathway mapping and competitor launch tracking.
Answer delivered
Adoption-barrier map, priority stakeholder segments and 12-month launch actions.
02
Pressure-test the payer value story
The question
Which evidence and messages will support access at the target price?
Evidence mix
Payer and HTA interviews, access benchmarking and targeted value-message testing.
Answer delivered
Evidence gaps, message hierarchy and the implications for price and access.
03
Select investigators and sites
The question
Which sites can recruit the right patients and execute the protocol?
Evidence mix
Investigator and site surveys, trial benchmarking, patient-pool and capability validation.
Answer delivered
A ranked investigator and site shortlist with a recruitment and execution risk map.
Case Studies
Pharma & Biotech Market Research
Pharma & Biotech Market Research
at work.
Separating practical AI use cases from the noise
Structured conversations with 12 peer leaders across clinical, regulatory and digital functions revealed where AI was adding value, the governance challenges to expect and the sensible first steps for adoption.
Read the case studyIdentifying what drives laboratory adoption
An expert-backed survey with 80 pathology and laboratory decision-makers isolated the service, training and data-integration factors that mattered most by region, supporting sharper pricing, support and account priorities.
Read the case studyMapping replacement demand across 1,000 sites
A center-by-center field program captured make, model and vintage across imaging equipment, creating a validated installed-base dataset for territory prioritization and replacement-demand sizing.
Read the case studyFinding where adoption and whitespace really sit
Surveys and interviews across 160+ hospitals and labs built an NGS lifecycle database, showing how adoption varies by testing model and where 15–20% whitespace remains for instrumentation, services and software.
Read the case studyPressure-testing the value story before launch
Interviews and surveys with health-plan and hospital decision-makers tested value messages, coverage assumptions and price corridors, giving the market-access team a clear view of likely payer objections and launch priorities.
Read the case studyBenchmarking the access conditions that shape uptake
Payer and clinician research identified reimbursement drivers, evidence expectations and pricing considerations across the oncology landscape, creating a comparative access benchmark to inform portfolio and value strategy.
Read the case studyFinding the pathway barriers delaying treatment initiation
Interviews with patients, caregivers, treating specialists and referral stakeholders mapped delays across symptom recognition, diagnosis, referral and treatment initiation, identifying the pathway changes and support interventions most likely to reduce time to therapy.
Read the case studyUnderstanding how Phase III data could reshape clinical practice
In-depth interviews with KOLs and practicing oncologists assessed the perceived differentiation of upcoming Phase III data, likely shifts in treatment algorithms and the scientific questions that remained unresolved, informing medical communications priorities.
Read the case studyMapping the real-world care model behind treatment decisions
Interviews with specialists, nurses and multidisciplinary care stakeholders mapped referral patterns, treatment sequencing and capacity constraints, revealing the practical care-delivery factors that could influence uptake of a future therapy.
Read the case studyPrioritizing the indications with the greatest strategic potential
KOL and payer interviews assessed unmet need, priority patient segments and feasibility across the immunology landscape, giving the strategy team a clear evidence base for portfolio choices and indication prioritization.
Read the case studyScreening the assets and partners worth pursuing
Expert and customer interviews tested the clinical relevance, commercial potential and execution risk of shortlisted assets and technologies, creating a comparative view to focus diligence and partnership discussions.
Read the case studyIdentifying where competitor perceptions created room to differentiate
Interviews with HCPs, payers and priority accounts compared competing brands on clinical confidence, access, service and messaging, revealing the perceived strengths to counter and the gaps the brand could credibly own.
Read the case study
Perspectives
Pharma & Biotech perspectives.
ArticleFrom clinical demand to funded persistenceObesity drug demand already outstrips supply. The next competitive line is funded access and whether patients stay on treatment, not efficacy alone.Read more
ArticleBeyond efficacy: the new battle for treatment preferenceAnti-CD20 therapy set the efficacy baseline in multiple sclerosis. The next competition is about route, treatment burden and where care can be delivered.Read more
ArticleCan RNA therapy redefine hypertension treatment?Long-acting RNA therapy could turn daily blood pressure pills into a twice-yearly injection. What zilebesiran proves, and what is still investigational.Read more
ArticleThe breast cancer ADC sequencing raceAntibody-drug conjugates work well enough now that treatment sequencing, not added efficacy, is deciding the next winner in breast cancer care.Read more
Start here
Tell us the decision you are facing.
Whether you have a project in mind, want to learn more about the practice, or are working a story, the right person gets back to you.
Discuss a project
Already have a decision in mind? Describe the project and the market it touches, and a research lead sets up an initial call to scope the evidence plan.
Start with a briefMedia inquiries
Working on a pharma or biotech story? We partner with journalists on data, expert commentary and named quotes drawn from our research base.
Contact the press deskPartnership inquiries
Running a conference, event or industry association? We partner as a knowledge partner, contributing research, speakers and data to your agenda.
Propose a partnership
Questions
Frequently asked questions
Research where the question is framed with therapy-area and clinical context, the right stakeholder is reached, and what is heard is connected across the market. Access alone is not enough: a scientifically uninformed question put to the right KOL still returns a weak answer.
KOLs and academic experts, treating physicians and HCPs, investigators and site teams, payers, HTA and formulary decision-makers, hospitals, labs and procurement, patients and advocacy groups, and industry leaders and partners.
Oncology, immunology, rare disease, cardiovascular, CNS, respiratory, and diagnostics and devices, across pharma, biotech, medtech, diagnostics and IVD, healthcare technology and healthcare services organizations.
Across all of it: discovery and asset strategy, clinical development, medical affairs, market access, launch and commercial, and in-market growth and portfolio decisions. The coverage section on this page sets out what each stage involves.
Yes. Payer and value message testing interviews payer and HTA decision-makers to test messages and surface evidence thresholds, trade-offs and access barriers. Pricing and access benchmarking compares payer criteria, access pathways and price corridors across markets.
Yes. Recent work includes a center-by-center field program capturing make, model and vintage across imaging equipment at 1,000 sites in India, building a validated installed-base dataset for territory and replacement-demand work.
Yes. Work is designed to be repeatable: one-off answers, dashboards and longitudinal trackers. Brand and launch pulse tracking follows HCP, payer and account signals on awareness, preference, prescribing, access and competitor activity over time.
Yes. Patient journey and care pathway work maps patient and caregiver experience alongside HCP perspectives to identify where people fall out of diagnosis, treatment or support, and which interventions are most likely to reduce time to therapy.
Per project, scoped against stakeholder mix, sample size, number of markets and method. The scope and the cost are agreed before any work begins.
Experts are screened for current employment and confidentiality obligations before a call is booked, briefed on what is out of scope, and reminded that material non-public information about a listed company stays with them. Every transcript is scanned before delivery.